JDRF T1D Fund
JDRF T1D Fund is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at JDRF T1D Fund.
JDRF T1D Fund is a company.
Key people at JDRF T1D Fund.
Key people at JDRF T1D Fund.
The JDRF T1D Fund, now known as the T1D Fund and operating as a Breakthrough T1D Venture, is a mission-driven venture philanthropy fund launched in 2016 as a subsidiary of Breakthrough T1D (formerly JDRF).[2][3][5] Its mission is to accelerate prevention, treatments, and cures for type 1 diabetes (T1D) by catalyzing equity investments in innovative T1D-focused companies, leveraging philanthropic capital to attract co-investments from venture capital, corporations, and foundations.[3][4][5] Unlike traditional VC firms, it reinvests all realized gains back into the fund rather than returning profits to donors, enabling perpetual impact; it has grown to over $200M in assets, catalyzed $900M+ in total investments, and sparked billions more from partners.[3][5] The fund targets key sectors like cell therapies, disease-modifying therapies, and novel mechanisms, providing not just capital but leadership support, expert networks, and guidance through development and regulatory approval, significantly boosting the T1D startup ecosystem by bridging research gaps and de-risking investments.[3][5]
The T1D Fund emerged in 2015-2016 from observations by JDRF leaders, including volunteers and executive chairman Sean Doherty, who noted zero venture investment in T1D despite untapped potential in JDRF's research expertise.[2][5] JDRF seeded the fund with $32M over four years, supplemented by $50M from ~70 private donors (minimum $500K donation, often T1D-connected), launching it in December 2016 as the world's first scaled venture philanthropy fund dedicated to T1D.[2][3][4] Key figures include Doherty and current board chair Jay Eastman; it evolved from a spark to catalyze private capital into a $200M+ powerhouse, operating independently while leveraging Breakthrough T1D's (founded 1970) global research and advocacy network.[3][5][6][7]
The T1D Fund rides the wave of advancing biotech trends in cell therapies, gene editing, and disease-modifying treatments for autoimmune diseases, filling a critical pre-2016 void in T1D private investment amid booming life sciences funding.[2][3][5] Timing is ideal with maturing T1D science (e.g., novel modalities) and regulatory momentum, amplified by market forces like rising chronic disease prevalence and philanthropic-tech convergence.[6] It influences the ecosystem by de-risking startups, signaling viability to VCs/pharma, and partnering with entities like Helmsley Trust, transforming T1D from research silo to investable sector with $billions mobilized.[3][5][6]
The T1D Fund is launching a bold new capital raise to scale investments in emerging T1D therapies, expanding scope to larger deals and novel mechanisms for faster regulatory progress.[6] Trends like AI-driven drug discovery, immunotherapy advances, and cross-disease learnings will shape its path, potentially unlocking cures sooner via bigger portfolio plays. Its influence will grow as the premier T1D investor, drawing more capital and solidifying its role in turning scientific promise into delivered breakthroughs—proving one focused fund can ignite a market for a world without T1D.[3][5][6]
